Hutchmed sells 45% stake in Shanghai venture for $608M, Xgene's pain drug succeeds in Phase 2b, Hookipa buys Poolbeg Pharma, and Capricor gets $10M from Nippon Shinyaku.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback